fbpx
Connect with us

Hi, what are you looking for?

UpNow Media

Finance

Takara Bio coronavirus vaccine to scale up better with Cytiva speedy support

Cytiva will provide support Takara Bio coronavirus vaccine development with Osaka University and AnGes, Inc. group

Takara Bio ramps up facilities to produce coronavirus vaccine.

If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates.

Cytiva to provide instruments and consumables to support Takara Bio’s effort to support development of DNA vaccine with Osaka University and AnGes, Inc. group

Takara Bio coronavirus vaccine to scale up better with Cytiva speedy support
Takara Bio coronavirus vaccine development has been a forerunner in the industry.

Cytiva (formerly part of GE Healthcare Life Sciences), a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics, is teaming up with Japan based Takara Bio to manufacture a DNA vaccine candidate for COVID-19.

Takara Bio coronavirus vaccine is a plasmid vaccine

In collaboration with Osaka University (Professor Ryuichi Morishita) and AnGes, Inc. group, Takara Bio is working on an innovative plasmid vaccine. The DNA vaccine would generate the SARS-CoV2 protein which would become an antigen, and help people develop immunity against the virus.

This plasmid DNA vaccine against COVID-19 is pioneering. Ryuichi Morishita, Professor at Osaka University, who designed the plasmid DNA, explains: “Beyond the potential clinical benefit of the vaccine, plasmid DNA allows faster response in case of outbreak of an infectious disease.” Plasmid DNA can be bio-manufactured in large quantities relatively quickly, allowing nimble ramp up of production.

Koichi Nakao, Takara Bio President and CEO, says: “Speed will make the difference in saving lives. With the right process design, prioritization of equipment and consumables, we can ramp up clinical production and accelerate the results of a clinical trial. As a CMO company, we are proud to be contributing to fast delivery of the vaccines and therefore helping defeat the COVID-19 pandemic as early as possible.”

Emmanuel Ligner, President and CEO of Cytiva, says: “For Japan and for the world, this is important to move quickly to tackle COVID-19 from diagnostics to therapies, like this potential vaccine. Cytiva’s entire organization is moving swiftly and decisively to respond to such a unique challenge. This work with Takara Bio, Osaka University and Anges is a great example of working together to improve access to life-changing therapies.”

DNA vaccines are said to be safely manufactured in a short period of time without using any dangerous pathogens. By injecting circular DNA (plasmid DNA) that encodes the protein of the target pathogen, the pathogen protein is produced in the body and immunity to the pathogen is generated. Unlike attenuated vaccines, it has no pathogenicity.

Other companies with potential vaccines

Another U.S. biotech company, Massachusetts-based Moderna, has already started a Phase 1 trial for its vaccine candidate and is reporting optimistic results, making shares jump last week.

Novavax, is starting trials for its vaccine candidate and is confident of producing 100m doses by end of 2020.

If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates.

Related Articles

Worldwide

Post Views: 114 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. There are more...

Worldwide

Post Views: 86 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. About 90 per...

Worldwide

Post Views: 78 If you like what you read, follow us on Facebook, Instagram and Twitter to get the latest updates. Japan and Singapore...

Japan

Nobuteru Taniguchi, Daigo Saito and a pair of GR Supra drift cars appear in a video promoting the new Tomica 'Happy Set' toy Drifting...

Advertisement
Advertisement
Advertisement
Advertisement